Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia

P. Nair, S. I. Ochkur, C. Protheroe, K. Radford, A. Efthimiadis, Nancy A Lee, J. J. Lee

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background Sputum eosinophilia has been shown to be a predictor of response to anti-eosinophil therapies in patients with airway diseases. However, quantitative cell counts and differentials of sputum are labor intensive. The objective of this study was to validate a novel ELISA-based assay of eosinophil peroxidase (EPX) in sputum as a rapid and reliable marker of airway eosinophils. Methods The utility of EPX-based ELISA as an eosinophil-specific assay was achieved through comparisons with sputum eosinophil differential counts in freshly prepared and archived patient samples from a variety of clinical settings. Results EPX levels in sputum correlated with eosinophil percentage (rs = 0.84) in asthma patients with varying degrees of airway eosinophilia. Significantly, unlike assays of other eosinophil granule proteins (e.g., ECP and EDN), which often detect the presence of these proteins even in asthma patients with neutrophilic bronchitis, EPX-based ELISA levels are not increased in this subset of asthma patients or in COPD patients lacking evidence of an airway eosinophilia. Moreover, sputum EPX was a surrogate marker of airway eosinophilia in other patient studies (e.g., allergen inhalation and treatment trials the anti-(IL-5) therapeutic Mepolizumab™). Finally, EPX levels in cytocentrifuged prepared sputum supernatants correlated with those from rapidly prepared noncentrifuged filtrates of sputum (rs = 0.94). Conclusion and clinical implication EPX-based ELISA is a valid, reliable, repeatable, and specific surrogate marker of eosinophils and/or eosinophil degranulation in the sputum of respiratory patients. The novel EPX assay is a valid and reproducible eosinophil-specific assay that can potentially be developed into a point-of-care assessment of eosinophil activity in airway secretions.

Original languageEnglish (US)
Pages (from-to)1177-1184
Number of pages8
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume68
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Eosinophil Peroxidase
Eosinophilia
Sputum
Eosinophils
Biomarkers
Enzyme-Linked Immunosorbent Assay
Asthma
Eosinophil Granule Proteins
Point-of-Care Systems
Bronchitis
Interleukin-5
Allergens
Chronic Obstructive Pulmonary Disease
Inhalation
Therapeutics
Cell Count

Keywords

  • asthma
  • COPD
  • ELISA
  • EPX
  • sputum eosinophils

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia. / Nair, P.; Ochkur, S. I.; Protheroe, C.; Radford, K.; Efthimiadis, A.; Lee, Nancy A; Lee, J. J.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 68, No. 9, 09.2013, p. 1177-1184.

Research output: Contribution to journalArticle

Nair, P. ; Ochkur, S. I. ; Protheroe, C. ; Radford, K. ; Efthimiadis, A. ; Lee, Nancy A ; Lee, J. J. / Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia. In: Allergy: European Journal of Allergy and Clinical Immunology. 2013 ; Vol. 68, No. 9. pp. 1177-1184.
@article{55430fcef6ef4f74a635e02503b3746c,
title = "Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia",
abstract = "Background Sputum eosinophilia has been shown to be a predictor of response to anti-eosinophil therapies in patients with airway diseases. However, quantitative cell counts and differentials of sputum are labor intensive. The objective of this study was to validate a novel ELISA-based assay of eosinophil peroxidase (EPX) in sputum as a rapid and reliable marker of airway eosinophils. Methods The utility of EPX-based ELISA as an eosinophil-specific assay was achieved through comparisons with sputum eosinophil differential counts in freshly prepared and archived patient samples from a variety of clinical settings. Results EPX levels in sputum correlated with eosinophil percentage (rs = 0.84) in asthma patients with varying degrees of airway eosinophilia. Significantly, unlike assays of other eosinophil granule proteins (e.g., ECP and EDN), which often detect the presence of these proteins even in asthma patients with neutrophilic bronchitis, EPX-based ELISA levels are not increased in this subset of asthma patients or in COPD patients lacking evidence of an airway eosinophilia. Moreover, sputum EPX was a surrogate marker of airway eosinophilia in other patient studies (e.g., allergen inhalation and treatment trials the anti-(IL-5) therapeutic Mepolizumab™). Finally, EPX levels in cytocentrifuged prepared sputum supernatants correlated with those from rapidly prepared noncentrifuged filtrates of sputum (rs = 0.94). Conclusion and clinical implication EPX-based ELISA is a valid, reliable, repeatable, and specific surrogate marker of eosinophils and/or eosinophil degranulation in the sputum of respiratory patients. The novel EPX assay is a valid and reproducible eosinophil-specific assay that can potentially be developed into a point-of-care assessment of eosinophil activity in airway secretions.",
keywords = "asthma, COPD, ELISA, EPX, sputum eosinophils",
author = "P. Nair and Ochkur, {S. I.} and C. Protheroe and K. Radford and A. Efthimiadis and Lee, {Nancy A} and Lee, {J. J.}",
year = "2013",
month = "9",
doi = "10.1111/all.12206",
language = "English (US)",
volume = "68",
pages = "1177--1184",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia

AU - Nair, P.

AU - Ochkur, S. I.

AU - Protheroe, C.

AU - Radford, K.

AU - Efthimiadis, A.

AU - Lee, Nancy A

AU - Lee, J. J.

PY - 2013/9

Y1 - 2013/9

N2 - Background Sputum eosinophilia has been shown to be a predictor of response to anti-eosinophil therapies in patients with airway diseases. However, quantitative cell counts and differentials of sputum are labor intensive. The objective of this study was to validate a novel ELISA-based assay of eosinophil peroxidase (EPX) in sputum as a rapid and reliable marker of airway eosinophils. Methods The utility of EPX-based ELISA as an eosinophil-specific assay was achieved through comparisons with sputum eosinophil differential counts in freshly prepared and archived patient samples from a variety of clinical settings. Results EPX levels in sputum correlated with eosinophil percentage (rs = 0.84) in asthma patients with varying degrees of airway eosinophilia. Significantly, unlike assays of other eosinophil granule proteins (e.g., ECP and EDN), which often detect the presence of these proteins even in asthma patients with neutrophilic bronchitis, EPX-based ELISA levels are not increased in this subset of asthma patients or in COPD patients lacking evidence of an airway eosinophilia. Moreover, sputum EPX was a surrogate marker of airway eosinophilia in other patient studies (e.g., allergen inhalation and treatment trials the anti-(IL-5) therapeutic Mepolizumab™). Finally, EPX levels in cytocentrifuged prepared sputum supernatants correlated with those from rapidly prepared noncentrifuged filtrates of sputum (rs = 0.94). Conclusion and clinical implication EPX-based ELISA is a valid, reliable, repeatable, and specific surrogate marker of eosinophils and/or eosinophil degranulation in the sputum of respiratory patients. The novel EPX assay is a valid and reproducible eosinophil-specific assay that can potentially be developed into a point-of-care assessment of eosinophil activity in airway secretions.

AB - Background Sputum eosinophilia has been shown to be a predictor of response to anti-eosinophil therapies in patients with airway diseases. However, quantitative cell counts and differentials of sputum are labor intensive. The objective of this study was to validate a novel ELISA-based assay of eosinophil peroxidase (EPX) in sputum as a rapid and reliable marker of airway eosinophils. Methods The utility of EPX-based ELISA as an eosinophil-specific assay was achieved through comparisons with sputum eosinophil differential counts in freshly prepared and archived patient samples from a variety of clinical settings. Results EPX levels in sputum correlated with eosinophil percentage (rs = 0.84) in asthma patients with varying degrees of airway eosinophilia. Significantly, unlike assays of other eosinophil granule proteins (e.g., ECP and EDN), which often detect the presence of these proteins even in asthma patients with neutrophilic bronchitis, EPX-based ELISA levels are not increased in this subset of asthma patients or in COPD patients lacking evidence of an airway eosinophilia. Moreover, sputum EPX was a surrogate marker of airway eosinophilia in other patient studies (e.g., allergen inhalation and treatment trials the anti-(IL-5) therapeutic Mepolizumab™). Finally, EPX levels in cytocentrifuged prepared sputum supernatants correlated with those from rapidly prepared noncentrifuged filtrates of sputum (rs = 0.94). Conclusion and clinical implication EPX-based ELISA is a valid, reliable, repeatable, and specific surrogate marker of eosinophils and/or eosinophil degranulation in the sputum of respiratory patients. The novel EPX assay is a valid and reproducible eosinophil-specific assay that can potentially be developed into a point-of-care assessment of eosinophil activity in airway secretions.

KW - asthma

KW - COPD

KW - ELISA

KW - EPX

KW - sputum eosinophils

UR - http://www.scopus.com/inward/record.url?scp=84884986382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884986382&partnerID=8YFLogxK

U2 - 10.1111/all.12206

DO - 10.1111/all.12206

M3 - Article

VL - 68

SP - 1177

EP - 1184

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 9

ER -